Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diakine Drug Conjugate (Autoimmune)
- Development stage
- Preclinical
- Lead developer
- DEKA Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Subcutaneous, Intratumoral, Intravenous
01
Overview
Diakine Drug Conjugate (Autoimmune) is a preclinical-stage therapeutic candidate being developed by DEKA Biosciences. It is a B cell-directed drug conjugate designed to selectively deplete or modulate autoreactive B cells, which play a central role in the pathogenesis of various autoimmune conditions. The drug is currently being investigated for the treatment of Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), and Myasthenia Gravis (MG). As part of DEKA's proprietary Diakine platform, this candidate likely utilizes a cytokine-based scaffold or targeting moiety to deliver a therapeutic payload directly to B cells, aiming to restore immune homeostasis while minimizing off-target systemic toxicity.
- Other names
- B cell-directed drug conjugate
02
Targets
IL10RA (Interleukin-10 Receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on Diakine Drug Conjugate (Autoimmune).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diakine Drug Conjugate (Autoimmune).